On May 11, 2017, Caladrius Biosciences, Inc. (the “Company,” “we,” or “our”) entered into a lease with 110 Allen Rod LLC (the “Landlord”) for our new Basking Ridge, New Jersey headquarters (the “New Lease”). The New Lease is for approximately 14,648 square feet of office space in Basking Ridge, New Jersey (the “Premises”). The term of the New Lease will commence on the later of (i) June 1, 2017 or (ii) the date on which the Landlord delivers the premises subject to the master lease to the Landlord with certain improvements substantially completed (the “Commencement Date”), and will expire sixty (60) months thereafter on June 1, 2022, unless terminated earlier.

During the term of the New Lease, the monthly base rent for the Premises will be approximately $23,781.33 during the first year, $24,266.67 during the second year, $24,752.00 during the third year, $25,237.33 during the fourth year, and $25,722 during the fifth and final year.

The information set forth in Item 1.02 below regarding the termination of our current office lease is incorporated by reference into this Item 1.01

Item 1.02 Termination of a Material Definitive Agreement

On May 11, 2017, we entered into a Lease Termination Agreement with 106 Allen Road LLC, which provides for the early termination of the existing lease for our current Basking Ridge, New Jersey headquarters (the “Original Lease”). The Original Lease is being terminated in connection with our execution of the New Lease described above under Item 1.01. The Original Lease was previously scheduled to expire on July 31, 2020. We will not be required to pay106 Allen Road LLC any termination payments or other penalties in connection with termination of the Original Lease.

Item 9.01. Financial Statement and Exhibits.>

(d) Exhibits.

Exhibit No. Description

10.1 Office Lease Between 110 Allen Road LLC, Landlord and Caladrius Biosciences, Inc.

10.2 Lease Termination Agreement Between 106 Allen Road LLC and Caladrius Biosciences, Inc.

About CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS)

Caladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development. The Company’s product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company’s T Regulatory Cell Technology is applicable to multiple autoimmune and allergic diseases.

CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) Recent Trading Information

CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) closed its last trading session up +0.04 at 5.37 with 69,014 shares trading hands.